Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank, has been granted renewed Foundation for the Accreditation of Cellular Therapy (“FACT ...
OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (CCEL) (NYSE American LLC: CCEL) (the “Company”, “Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells ...
The body’s “killer” T cells don’t just attack—they strike with astonishing precision, forming a tiny, highly organized ...
The Company reported net income of $356,000, or $0.04 per basic and diluted common shares for the three months ended May 31, 2025, compared to net income of $656,000, or $0.08 per basic and diluted ...
A collaboration between the University of Geneva and Lausanne University Hospital has shown in new detail how the body's defenses fight back against malignant cells. Those defenses involve T ...
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced ...
Cytotoxic T lymphocytes are the body's specialized "killer" cells, precisely eliminating infected or cancerous cells.
The Company reported net income of approximately $47,000 or $0.01 per basic and diluted common share for the three months ended February 28, 2026, compared to net income of approximately $283,000, or ...
OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (CCEL) (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results